Matthew Carlson, MD
Gynecologic Oncology · McKinney, TXNPI 1528268463
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,358 of the $24,645 with a category attached, or 82.6%. 24 manufacturers reported payments, led by Spectrum Pharmaceuticals Inc. at 38.9% of the total. Reporting peaked in 2024 at $9,986 and has fallen 54.2% since, to $4,575 in 2025.
Across 81 payments — averaging $304.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spectrum Pharmaceuticals Inc.$10K
- AstraZeneca$6K
- Merck$2K
- Seagen Inc.$2K
- GSK$1K
- Astrazeneca UK Limited$954
- plus $2K from 18 others
Across 75 payments — averaging $4185.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$174K
- GSK$87K
- Tesaro, Inc.$53K
What the payments were for
- Consulting fees$20,35883%
- Travel & lodging$1,4966%
- Food & beverage$2,39010%
- Education$4012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spectrum Pharmaceuticals Inc. | 7 | $9,592 |
| AstraZeneca | 15 | $6,383 |
| Merck | 4 | $2,321 |
| Seagen Inc. | 1 | $1,925 |
| GSK | 6 | $1,096 |
| Astrazeneca UK Limited | 8 | $954 |
| Stryker | 5 | $939 |
| Medical Device Business Services, Inc. | 1 | $325 |
| Clovis Oncology, Inc. | 3 | $203 |
| Tesaro, Inc. | 4 | $203 |
| Daiichi Sankyo Inc. | 4 | $108 |
| Abbott | 1 | $102 |
| Caris MPI, Inc. | 3 | $83 |
| Johnson & Johnson | 4 | $82 |
| Myriad Genetic Laboratories, Inc. | 4 | $67 |
| Eisai Inc. | 2 | $47 |
| Novartis | 2 | $38 |
| Genmab U.S., Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Geron Corporation | 1 | $23 |
| AbbVie | 1 | $22 |
| Immunogen, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROLVEDON$9,552
- LYNPARZA$2,190
- ZEJULA$1,095
- 1588 HD 3 CHIP CAMERA$738
- IMFINZI$656
- Rubraca$117
- SPY-PHI SYSTEM$105
- ASSURITY$102
How this compares
$24,645 in reported general payments places this provider in the 80th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 14 | $635 |
| Ondansetron OdtOndansetron | 21 | $298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $237 |
| Oxycodone Hcl | 12 | $70 |
| Tramadol Hcl | 19 | $45 |
| Prednisone | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in McKinney
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
- Eugene ToyEl Paso$138K
- Aparna KamatHouston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.